NOT AN OFFER TO INVEST. RED HERRING DISCLOSURE AVAILABLE ON REQUEST. PROFESSIONAL INVESTORS ONLY.

HEALTH. Covid backlash hobbles public health and future pandemic response. The Washington Post.

HEALTH Covid backlash hobbles public health and future pandemic response [...]

By |2023-03-08T21:30:47+00:00March 8, 2023|Blog Posts|Comments Off on HEALTH. Covid backlash hobbles public health and future pandemic response. The Washington Post.
Read More

THE BMJ. Research. The US government invested at least $31.9bn to develop, produce, and purchase mRNA covid-19 vaccines.

Research US public investment in development of mRNA covid-19 vaccines: [...]

By |2023-03-08T22:15:34+00:00March 7, 2023|Blog Posts|Comments Off on THE BMJ. Research. The US government invested at least $31.9bn to develop, produce, and purchase mRNA covid-19 vaccines.
Read More

THE BMJ. Editorials. Financing covid-19 mRNA vaccines. $100billion since launch of covid-19 vaccines. Moderna and Pfizer have accumulated more than $100bn in global sales revenues.

Editorials Financing covid-19 mRNA vaccines BMJ 2023; 380 doi: https://doi.org/10.1136/bmj.p413 [...]

By |2023-03-08T22:16:14+00:00March 7, 2023|Blog Posts|Comments Off on THE BMJ. Editorials. Financing covid-19 mRNA vaccines. $100billion since launch of covid-19 vaccines. Moderna and Pfizer have accumulated more than $100bn in global sales revenues.
Read More

DR ERIC TOPOL. GROUND TRUTHS. Heart attacks and strokes late after Covid. The body of evidence expands.

DR ERIC TOPOL. GROUND TRUTHS. Heart attacks and strokes late [...]

By |2023-03-05T22:58:49+00:00March 5, 2023|Blog Posts|Comments Off on DR ERIC TOPOL. GROUND TRUTHS. Heart attacks and strokes late after Covid. The body of evidence expands.
Read More

The New York Times. Is the United States Ready for Back-to-Back Pandemics? Feb. 22, 2023

Is the United States Ready for Back-to-Back Pandemics? Feb. 22, [...]

By |2023-02-26T21:54:01+00:00February 26, 2023|Blog Posts|Comments Off on The New York Times. Is the United States Ready for Back-to-Back Pandemics? Feb. 22, 2023
Read More

THE LANCET. One-Fourth of COVID-19 Patients Have an Impaired Pulmonary Function after 12 Months of Illness Onset. 24 Feb 2023

One-Fourth of COVID-19 Patients Have an Impaired Pulmonary Function after [...]

By |2023-02-26T21:26:23+00:00February 26, 2023|Blog Posts|Comments Off on THE LANCET. One-Fourth of COVID-19 Patients Have an Impaired Pulmonary Function after 12 Months of Illness Onset. 24 Feb 2023
Read More

NATURE. US$3.57 TRILLION LOST. Assessing the impact of one million COVID-19 deaths in America: economic and life expectancy losses.

NATURE. Assessing the impact of one million COVID-19 deaths [...]

By |2023-02-23T16:45:51+00:00February 23, 2023|Blog Posts|Comments Off on NATURE. US$3.57 TRILLION LOST. Assessing the impact of one million COVID-19 deaths in America: economic and life expectancy losses.
Read More

FACE THE NATION. Senator Bernie Sanders On COVID vaccine pricing: “Truth is, the pharmaceutical industry is enormously greedy, charging us outrageously uncontrollably high prices…”

Sanders targets drug companies over COVID-19 vaccine price hikes, [...]

By |2023-02-20T04:11:30+00:00February 20, 2023|Blog Posts|Comments Off on FACE THE NATION. Senator Bernie Sanders On COVID vaccine pricing: “Truth is, the pharmaceutical industry is enormously greedy, charging us outrageously uncontrollably high prices…”
Read More

WSJ. Making Medical Science More Democratic. Patient groups are collaborating with medical researchers as never before, creating a new model for progress against long Covid and other diseases

Making Medical Science More Democratic. Patient groups are collaborating with [...]

By |2023-02-18T19:22:15+00:00February 18, 2023|Blog Posts|Comments Off on WSJ. Making Medical Science More Democratic. Patient groups are collaborating with medical researchers as never before, creating a new model for progress against long Covid and other diseases
Read More
Forward Looking Statements. No Offer or Solicitation. Professional Investors Only.2023-02-03T11:00:00+00:00

This website includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “will,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements about our beliefs and expectations and the estimated financial information and other projections contained herein. Such forward-looking statements with respect to revenues, earnings, performance, strategies, prospects and other aspects of the businesses of Normax Biomed Ltd. are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those expressed or implied by such forward-looking statements. Please refer to the final prospectus of Normax Biomed Limited under “Risk Factors” therein, and other documents filed or to be filed with the London Stock Exchange and the Swiss Stock Exchange (SIX) by Normax Biomed Ltd. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Normax Biomed Ltd. undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

The information on this website shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. The information on this website shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the listing requirements of the London Stock Exchange and the Swiss Stock Exchange (SIX).

This website is directed only at, and provides information about products and services only available to, those who are Professional Clients or Eligible Counterparties as defined by the Financial Conduct Authority. The definitions can be found on the FCA website at www.fca.org.uk. This website is not intended to be accessed by any persons or entities domiciled in any jurisdiction where being treated as the types of clients stated would be contrary to local law.

Normax Abstract2022-08-31T11:50:39+00:00

Normax Biomed Ltd (Normax) is based in Cork, Ireland, and London, England. Normax is in the business of mRNA vaccine Research, Development and Manufacturing. Normax has secured a €300,000,000 capital commitment from a $3.4Bn cornerstone institutional investor for development of mRNA Vaccines and Vax Factory Manufacturing for Transformative Social Impact on Infectious Disease and Pandemic Preparedness. Normax plans to drive down the cost of mRNA Vaccines to save more lives and to deliver sustainable returns for impact investors. Normax plans to deliver safe and effective mRNA vaccines at large scale for about $4 dollars per dose. Normax mRNA vaccine products in development include: (1) mRNA Vax Factory, (2) Universal Coronavirus mRNA Vaccine, (3) Tuberculosis mRNA Vaccine, (4) HIV mRNA Vaccine, (5) Malaria mRNA Vaccine, and (6) Disease-X mRNA Vaccine (e.g. within 100 days). Normax mission is to deliver competitive financial performance with transformative social impact. NOT AN OFFER TO INVEST.

Copyright 2021 | Normax Biomed Limited | First Floor, Penrose 1, Penrose Dock, Cork, Ireland | T23 KW81 | Company Number 669518

error: Content is protected !!
Go to Top